<SEC-DOCUMENT>0001013762-23-002972.txt : 20231011
<SEC-HEADER>0001013762-23-002972.hdr.sgml : 20231011
<ACCEPTANCE-DATETIME>20231011070009
ACCESSION NUMBER:		0001013762-23-002972
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231011
FILED AS OF DATE:		20231011
DATE AS OF CHANGE:		20231011

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		231319405

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea186576-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>October 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commission File Number:</B>&nbsp; <B>001-38723</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tiziana Life Sciences LTD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Form&nbsp;40-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif">On October 11, 2023, Tiziana Life Sciences LTD (the
&ldquo;<U>Company</U>&rdquo;) issued a press release, announcing a late breaking poster titled, &ldquo;Treatment Of Six Non-Active Secondary
Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes&rdquo;, will be presented
at the 39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) being held in Milan, Italy,
October 11-13, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif">The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form&nbsp;6-K.
The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section&nbsp;18
of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated
by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934,
except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: October 11, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit<BR>
No.</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&#9;</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea186576ex99-1_tiziana.htm" STYLE="-sec-extract: exhibit">News Service Announcement, dated October 11, 2023</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea186576ex99-1_tiziana.htm
<DESCRIPTION>NEWS SERVICE ANNOUNCEMENT, DATED OCTOBER 11, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #3E9CB9"><IMG SRC="image_001.jpg" ALT="Primary Logo" STYLE="height: 34px; width: 150px"></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 12pt">Tiziana
Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive
Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; color: #252525"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Late-breaking
                                            poster to be presented titled: &ldquo;Treatment Of Six Non-Active Secondary Progressive MS
                                            With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #252525"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt; color: #252525">NEW YORK,&nbsp;October 11,
2023 -- Tiziana Life Sciences Ltd.&nbsp;(Nasdaq: </FONT><FONT STYLE="font-size: 10pt"><U>TLSA</U><FONT STYLE="color: #252525">) (&ldquo;Tiziana&rdquo;
or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough immunomodulation </FONT>therapies via novel routes of
drug delivery, today announced a late breaking poster titled, &ldquo;Treatment Of Six Non-Active Secondary Progressive MS With Nasal
Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes&rdquo;, will be presented at the 39th Congress of
the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) being held in Milan, Italy, October 11-13, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 10pt"><B>About
ECTRIMS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #3C3C3C"><FONT STYLE="font-size: 10pt; background-color: white">The
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is a non-profit organization and an independent representative
European-wide organization devoted to multiple sclerosis (MS). It serves as Europe&rsquo;s and the world&rsquo;s largest professional
organization dedicated to the understanding and treatment of MS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #3C3C3C"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt; color: #3C3C3C; background-color: white">The
annual meeting of ECTRIMS is the world&rsquo;s largest MS research meeting. This year marks the 9th Joint ECTRIMS-ACTRIMS Meeting, which
takes place 11-13 October 2023 in Milan, Italy.</FONT> <FONT STYLE="font-size: 10pt; color: white; background-color: white">the most relevant
issues facing MS and neurological experts today.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 10pt"><B>About
Foralumab</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 10pt">Activated
T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds
to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune
cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects.
The non-active SPMS intranasal foralumab Phase 2 trial is expected to start screening in November of 2023. Immunomodulation by nasal
anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.<SUP>1,2</SUP></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP></FONT><FONT STYLE="font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2220272120<BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2
</SUP></FONT>https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 10pt"><B>About&nbsp;Tiziana
Life Sciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE"><FONT STYLE="font-size: 10pt; color: #252525">Tiziana
Life Sciences&nbsp;is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery
technologies to enable alternative routes of immunotherapy. </FONT><FONT STYLE="font-size: 10pt; color: #4A4A4A">Tiziana&rsquo;s innovative
nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV)
delivery.&nbsp;</FONT> <FONT STYLE="font-size: 10pt; color: #252525">Tiziana&rsquo;s lead candidate, intranasal foralumab, which is the
only fully human anti-CD3 mAb, has demonstrated a favorable sa</FONT><FONT STYLE="font-size: 10pt">fety profile and clinical response
in patients in studies to date. Tiziana&rsquo;s technology for alternative routes of immunotherapy has been patented with several applications
pending and is expected to allow for broad pipeline applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 10pt">For
further inquiries:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE; color: #252525"><FONT STYLE="font-size: 10pt"><B>Tiziana
Life Sciences Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE"><FONT STYLE="font-size: 10pt">Paul
Spencer, Business Development and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;<U>info@tizianalifesciences.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; background-color: #FEFEFE"><FONT STYLE="font-size: 10pt"><B>Investors:</B><BR>
Irina Koffler<BR>
LifeSci Advisors, LLC<BR>
+1 646 970 4681<BR>
<U>ikoffler@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B )8# 2(  A$! Q$!_\0
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MB/\ 8^LBT&/]5Y8!;_@?45XUK6B:W'=/%JLMV\O_ $VD+9^A)Y%=-XDU?7/
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31L#& 51L@'#-R!W/K1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
